Float Short %

21.15

Margin Of Safety %

Put/Call OI Ratio

0.62

EPS Next Q Diff

0.31

EPS Last/This Y

-1.41

EPS This/Next Y

0.61

Price

5.41

Target Price

24.29

Analyst Recom

2.22

Performance Q

-64.57

Relative Volume

0.95

Beta

-0.08

Ticker: PRTA

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-08	PRTA	7.07	1.37	0.84	16671
2025-05-09	PRTA	7.42	1.36	2.13	17603
2025-05-12	PRTA	7.62	1.39	6.84	18650
2025-05-13	PRTA	7.58	1.69	1.08	21736
2025-05-14	PRTA	6.89	1.68	0.71	22451
2025-05-15	PRTA	6.71	1.51	0.39	23931
2025-05-16	PRTA	7.17	1.35	0.65	26014
2025-05-19	PRTA	7.39	1.43	0.52	28281
2025-05-20	PRTA	7.28	1.36	0.99	29350
2025-05-21	PRTA	6.82	1.52	0.13	31674
2025-05-22	PRTA	6.55	1.42	0.47	32682
2025-05-23	PRTA	6.58	1.26	0.43	36598
2025-05-27	PRTA	4.55	1.11	2.22	41960
2025-05-28	PRTA	4.6	0.67	0.42	37854
2025-05-29	PRTA	4.7	0.58	0.40	39047
2025-05-30	PRTA	4.59	0.61	3.09	39313
2025-06-02	PRTA	4.66	0.67	1.25	41811
2025-06-03	PRTA	4.84	0.66	0.59	41687
2025-06-04	PRTA	4.87	0.66	0.22	41714
2025-06-05	PRTA	5.05	0.66	0.87	41703
2025-06-06	PRTA	5.41	0.62	2.56	41529
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-08	PRTA	7.07	23.0	-	-3.58
2025-05-09	PRTA	7.43	23.0	-	-3.58
2025-05-12	PRTA	7.61	23.0	-	-3.58
2025-05-13	PRTA	7.59	23.0	-	-3.58
2025-05-14	PRTA	6.88	23.0	-	-3.58
2025-05-15	PRTA	6.71	23.0	-	-3.58
2025-05-16	PRTA	7.18	23.0	-	-3.58
2025-05-19	PRTA	7.40	-184.4	-	-3.57
2025-05-20	PRTA	7.29	-184.4	-	-3.57
2025-05-21	PRTA	6.83	-184.4	-	-3.57
2025-05-22	PRTA	6.54	-184.4	-	-3.57
2025-05-23	PRTA	6.57	-184.4	-	-3.57
2025-05-27	PRTA	4.58	-184.4	-	-3.57
2025-05-28	PRTA	4.60	-184.4	-	-3.57
2025-05-29	PRTA	4.70	-184.4	-	-3.57
2025-05-30	PRTA	4.59	-184.4	-	-3.57
2025-06-02	PRTA	4.66	-185.3	-	-3.68
2025-06-03	PRTA	4.83	-185.3	-	-3.68
2025-06-04	PRTA	4.87	-185.3	-	-3.68
2025-06-05	PRTA	5.06	-185.3	-	-3.68
2025-06-06	PRTA	5.41	-185.3	-	-3.68
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-08	PRTA	-47.56	6.70	16.81
2025-05-09	PRTA	-47.56	6.70	16.81
2025-05-12	PRTA	-47.56	-9.79	15.82
2025-05-13	PRTA	-47.56	-9.79	15.82
2025-05-14	PRTA	-47.56	-9.79	15.82
2025-05-15	PRTA	-47.56	-9.79	15.82
2025-05-16	PRTA	-47.56	-9.79	15.82
2025-05-19	PRTA	-47.56	-11.97	17.63
2025-05-20	PRTA	-34.43	-11.97	17.61
2025-05-21	PRTA	-34.54	-11.97	17.61
2025-05-22	PRTA	-34.54	-11.97	17.61
2025-05-23	PRTA	-34.54	-11.97	17.61
2025-05-27	PRTA	-34.54	-16.45	17.61
2025-05-28	PRTA	-34.54	-16.45	21.15
2025-05-29	PRTA	-34.54	-16.45	21.15
2025-05-30	PRTA	-34.54	-16.45	21.15
2025-06-02	PRTA	-34.54	-16.18	21.15
2025-06-03	PRTA	-34.54	-16.18	21.15
2025-06-04	PRTA	-34.54	-16.18	21.15
2025-06-05	PRTA	-34.54	-16.18	21.15
2025-06-06	PRTA	-34.54	-16.18	21.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.12

Avg. EPS Est. Current Quarter

-1.04

Avg. EPS Est. Next Quarter

-0.81

Insider Transactions

-34.54

Institutional Transactions

-16.18

Beta

-0.08

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.2

Max Drawdown 5-Year %

-94.2

Target Price

24.29

P/E

Forward P/E

PEG

P/S

2.11

P/B

0.67

P/Free Cash Flow

EPS

-2.08

Average EPS Est. Cur. Y

-3.68

EPS Next Y. (Est.)

-3.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-79.94

Relative Volume

0.95

Return on Equity vs Sector %

-49.2

Return on Equity vs Industry %

-31.3

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.1

EBIT Estimation

Prothena Corporation plc

Sector: Healthcare

Industry: Biotechnology

Employees: 163

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

stock quote shares PRTA -Prothena Corporation plc Stock Price stock today

news today PRTA -Prothena Corporation plc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRTA -Prothena Corporation plc yahoo finance google finance

stock history PRTA -Prothena Corporation plc invest stock market

stock prices PRTA premarket after hours

ticker PRTA fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PRTA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y